ITP
DNTH icon

Iron Triangle Partners’s Dianthus Therapeutics DNTH Stock Holding History

Iron Triangle Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.51M Buy
+230,730
New +$8.95M 1.09% 26

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Iron Triangle Partners's DNTH Position: Q4 2025 in Review

Iron Triangle Partners opened a new position in Dianthus Therapeutics (DNTH) in Q4 2025: 230,730 shares worth $9.51M. The stake represents 1.09% of the portfolio and ranks #26 among its holdings.

165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Iron Triangle Partners held 230,730 shares of Dianthus Therapeutics worth $9.51M as of Q4 2025.
  • Dianthus Therapeutics was a new Iron Triangle Partners position in Q4 2025.
  • Dianthus Therapeutics made up 1.09% of Iron Triangle Partners's portfolio in Q4 2025, its #26 holding.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.